Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.16
RGDX's Cash to Debt is ranked lower than
90% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. RGDX: 0.16 )
Ranked among companies with meaningful Cash to Debt only.
RGDX' s 10-Year Cash to Debt Range
Min: 0.16  Med: 9999.00 Max: No Debt
Current: 0.16
Equity to Asset -0.46
RGDX's Equity to Asset is ranked lower than
97% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. RGDX: -0.46 )
Ranked among companies with meaningful Equity to Asset only.
RGDX' s 10-Year Equity to Asset Range
Min: -0.81  Med: 0.06 Max: 0.7
Current: -0.46
-0.81
0.7
F-Score: 2
Z-Score: -12.67
M-Score: -3.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -79.27
RGDX's Operating margin (%) is ranked lower than
73% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. RGDX: -79.27 )
Ranked among companies with meaningful Operating margin (%) only.
RGDX' s 10-Year Operating margin (%) Range
Min: -138.39  Med: -40.50 Max: 27.64
Current: -79.27
-138.39
27.64
Net-margin (%) -85.54
RGDX's Net-margin (%) is ranked lower than
75% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.26 vs. RGDX: -85.54 )
Ranked among companies with meaningful Net-margin (%) only.
RGDX' s 10-Year Net-margin (%) Range
Min: -133.14  Med: -40.96 Max: 27.86
Current: -85.54
-133.14
27.86
ROE (%) -2120.08
RGDX's ROE (%) is ranked lower than
99% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.76 vs. RGDX: -2120.08 )
Ranked among companies with meaningful ROE (%) only.
RGDX' s 10-Year ROE (%) Range
Min: -597.04  Med: -248.43 Max: -86.33
Current: -2120.08
-597.04
-86.33
ROA (%) -105.96
RGDX's ROA (%) is ranked lower than
89% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.65 vs. RGDX: -105.96 )
Ranked among companies with meaningful ROA (%) only.
RGDX' s 10-Year ROA (%) Range
Min: -86.97  Med: -49.98 Max: -21.82
Current: -105.96
-86.97
-21.82
ROC (Joel Greenblatt) (%) -312.72
RGDX's ROC (Joel Greenblatt) (%) is ranked lower than
75% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.66 vs. RGDX: -312.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RGDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -699.51  Med: -365.29 Max: -219.24
Current: -312.72
-699.51
-219.24
Revenue Growth (3Y)(%) -28.60
RGDX's Revenue Growth (3Y)(%) is ranked lower than
84% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. RGDX: -28.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RGDX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -32.5  Med: -14.80 Max: 19
Current: -28.6
-32.5
19
EBITDA Growth (3Y)(%) 3.50
RGDX's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. RGDX: 3.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RGDX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30.9  Med: -14.50 Max: 23
Current: 3.5
-30.9
23
EPS Growth (3Y)(%) 5.30
RGDX's EPS Growth (3Y)(%) is ranked higher than
55% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. RGDX: 5.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RGDX' s 10-Year EPS Growth (3Y)(%) Range
Min: -31.4  Med: -15.70 Max: 5.3
Current: 5.3
-31.4
5.3
» RGDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with RGDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 0.27
RGDX's P/S is ranked higher than
92% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.22 vs. RGDX: 0.27 )
Ranked among companies with meaningful P/S only.
RGDX' s 10-Year P/S Range
Min: 0.27  Med: 2.00 Max: 4.34
Current: 0.27
0.27
4.34
EV-to-EBIT -1.04
RGDX's EV-to-EBIT is ranked higher than
98% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.37 vs. RGDX: -1.04 )
Ranked among companies with meaningful EV-to-EBIT only.
RGDX' s 10-Year EV-to-EBIT Range
Min: -19.1  Med: -3.35 Max: 0.9
Current: -1.04
-19.1
0.9
Current Ratio 1.80
RGDX's Current Ratio is ranked lower than
71% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. RGDX: 1.80 )
Ranked among companies with meaningful Current Ratio only.
RGDX' s 10-Year Current Ratio Range
Min: 1.14  Med: 2.20 Max: 5.28
Current: 1.8
1.14
5.28
Quick Ratio 1.80
RGDX's Quick Ratio is ranked lower than
60% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. RGDX: 1.80 )
Ranked among companies with meaningful Quick Ratio only.
RGDX' s 10-Year Quick Ratio Range
Min: 1.14  Med: 2.20 Max: 5.28
Current: 1.8
1.14
5.28
Days Sales Outstanding 133.10
RGDX's Days Sales Outstanding is ranked lower than
87% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.88 vs. RGDX: 133.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGDX' s 10-Year Days Sales Outstanding Range
Min: 37.3  Med: 92.94 Max: 197.12
Current: 133.1
37.3
197.12

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.14
RGDX's Price/Median PS Value is ranked higher than
92% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. RGDX: 0.14 )
Ranked among companies with meaningful Price/Median PS Value only.
RGDX' s 10-Year Price/Median PS Value Range
Min: 0.36  Med: 0.99 Max: 2.04
Current: 0.14
0.36
2.04
Earnings Yield (Greenblatt) (%) -96.20
RGDX's Earnings Yield (Greenblatt) (%) is ranked higher than
99% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. RGDX: -96.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RGDX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -1858.86  Med: 108.70 Max: 3515.05
Current: -96.2
-1858.86
3515.05

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Response Genetics Inc was incorporated in the State of Delaware on September 23, 1999. It is a life sciences company engaged in the research and development of clinical diagnostic tests for cancer. The Company currently generates revenues mainly from sales of its ResponseDX diagnostic tests, which it launched in 2008 and by providing clinical trial testing services to pharmaceutical companies. It has developed technologies for the extraction of RNA from FFPE tissues which enable it to reliably recover RNA suitable for a variety of applications, such as gene expression research, development of diagnostics, and microarray platforms. In addition, its technologies permit gene profiling analysis of current clinical trials, of which use the paraffin embedding technique for tissue specimen storage. The Company developed and patented extraction methodologies that allow reliable and consistent isolation of RNA and DNA from FFPE suitable for use in various types of analysis. The Company validated its methodology, which particularly addressed issues of recovery of RNA, accuracy, and precision. Further, its methodologies allow for rapid extraction of RNA with little or no DNA contamination, which makes it suitable for large-scale analysis. The Company developed ResponseDX in part by using its technology to extract genetic information from FFPE tumor specimens. Its technology provides gene expression information for each patient's tumor tissue specimen. It has developed assays for the targets comprising the ResponseDX profiles for use in its CLIA lab. Assay development of these tests was done through appropriate validation procedures which determine the accuracy of each test. The Company offers ResponseDX testing services nationwide. Its main sales include community based oncologists, pathologists, physician offices and hospitals. The Company's actual competitors in the United States and abroad may include clinical and pathology laboratories, such as Quest Diagnostics Inc., Laboratory Corporation of America, Clarient, Inc. (acquired by GE), and laboratories such as Genoptixs Inc. (acquired by Novartis Pharmaceuticals), NeoGenomics, Inc., Caris Life Sciences, Foundation Medicine, university laboratories and other research institutions. The Company is subject to various regulatory requirements designed to ensure the quality and integrity of its non-clinical testing processes. Its business is also subject to regulation under state and federal laws regarding environmental protection and hazardous substances control, such as the Federal Occupational Safety and Health Act, the Environmental Protection Act, and Toxic Substances Control Act.
» More Articles for RGDX

Headlines

Articles On GuruFocus.com
A New Beginning for Codexis? Mar 08 2013 
Response Genetics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Response Genetics Inc. Reports Operating Results (10-Q) May 14 2010 
Weekly CFO Buys Highlight: CONSTELLATION ENERGY, DPL Inc., Taylor Capital Group Inc., Physicians For Dec 19 2009 
Response Genetics Inc. (RGDX) CFO Thomas Stankovich buys 7,000 Shares Dec 14 2009 
Response Genetics Inc. Reports Operating Results (10-Q) Nov 16 2009 
Response Genetics Inc. Reports Operating Results (10-Q) Aug 21 2009 
Response Genetics, Inc. Reports Second Quarter 2009 Financial Results Driven by 70% Increase From Re Aug 13 2009 
Response Genetics, Inc. to Release Second Quarter 2009 Financial Results Aug 07 2009 
Response Genetics Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
RESPONSE GENETICS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Jul 06 2015
3 Stocks Under $10 Triggering Breakout Trades Jul 02 2015
RESPONSE GENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Jul 01 2015
Great Basin Welcomes Kirk Calhoun to Board of Directors Jun 02 2015
RESPONSE GENETICS INC Financials May 27 2015
10-Q for Response Genetics, Inc. May 17 2015
RESPONSE GENETICS INC Files SEC form 10-Q, Quarterly Report May 15 2015
Response Genetics, Inc. Announces First Quarter 2015 Financial Results May 14 2015
RESPONSE GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 14 2015
Q1 2015 Response Genetics Inc Earnings Release - Before Market Open May 14 2015
Response Genetics, Inc. Announces First Quarter 2015 Financial Results May 14 2015
Response Genetics, Inc. to Release First Quarter 2015 Financial Results and Host Conference Call on... May 07 2015
Response Genetics, Inc. to Release First Quarter 2015 Financial Results and Host Conference Call on... May 07 2015
RESPONSE GENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Apr 08 2015
Response Genetics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results Mar 31 2015
RESPONSE GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 31 2015
RESPONSE GENETICS INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 20 2015
Response Genetics, Inc. to Release Fourth Quarter and Year-End 2014 Financial Results and Host... Mar 19 2015
RESPONSE GENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Feb 06 2015
RESPONSE GENETICS INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Creation of... Jan 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK